BRITISH BIOTECH SAYS MARIMASTAT OFFERS NO BENEFITS.British Biotech British Biotech was a British based biotech company. British Biotechnology Limited was founded in 1986 by former G D Searle managers Keith McCullagh and Brian Richards, [1] , Oxford, England, has reported the results of Study 131, a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the of the oral matrix metalloproteinase inhibitor, marimastat. This trial was designed to study the effect of marimastat compared to placebo in prolonging survival of patients with glioblastoma glioblastoma /glio·blas·to·ma/ (gli?o-blas-to´mah) any malignant astrocytoma. glioblastoma multifor´me , a form of brain cancer. Treatment with marimastat showed no statistically significant advantage over placebo in either primary or secondary endpoints. Elliot Goldstein, British Biotech's chief executive, commented: "Glioblastoma is an aggressive cancer with few treatment options and, unfortunately, marimastat does not offer any benefit to patients with this disease. Two studies in small cell lung cancer Lung Cancer, Small Cell Definition Small cell lung cancer is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. Description Lung cancer is divided into two main types: small cell and non-small cell. , which we believe represents the most suitable setting in which marimastat is being tested, will report later this year." British Biotech is a development-stage pharmaceutical company which is building a portfolio of products for the treatment of cancer, inflammation and infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. . These opportunities will be generated from in-house research and development and by acquisition from, and collaboration with, outside parties. British Biotech currently has six products in development. Its lead product, marimastat, a matrix metalloproteinase inhibitor, is in Phase III development for the treatment of cancer and has been licensed worldwide to Schering-Plough Corporation except for Japan and the Far East where it has been licensed to Tanabe Seiyaku Co., Ltd. Other products in development are: BB-3644, a follow-on to marimastat, for cancer; BB-10153 for cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease ; BB-2827 for inflammation; huN901-DM1 for small cell lung cancer; and BB-76163 for chronic inflammatory disease. For more informaton, call 011-44-1865-781166. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion